An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation

Supportive Care in Cancer

Volumn 6, Issue 6, 1998, Pages 511-517

  Osowski, Cynthia L ^a,f   Dix, Suzanne P ^b   Lynn, Mike ^c   Davidson, Terri ^a   Cohen, Lisa ^c   Miyahara, Tammi ^a   Sexauer, Mary C ^d   Joyce, Robert ^d   Yeager, Andrew ^a   Wingard, John R ^e  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b Oncol Hematol Assoc Kansas City   (United States)

^c EMORY UNIVERSITY   (United States)

^d BAPTIST MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f NONE   (United States)

Author keywords

Bone marrow transplantation; Nausea; Ondansetron; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; HALOPERIDOL; LORAZEPAM; ONDANSETRON; PROCHLORPERAZINE; THIOTEPA;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG INTERMITTENT THERAPY; FEMALE; HEADACHE; HUMAN; INDIGESTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; ONDANSETRON; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING;

EID: 7844241232     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050206     Document Type: Article

References (25)

1. Abbott B, Ippoliti C, Neumann J, et al (1996) Standard practice protocol of granisetron (Kytril) for antiemetic control in bone marrow transplant (BMT) patients receiving highly emetogenic chemotherapy with or without total body irradiation (TBI). Blood 88 [S1]:a3737:252b
2. Agura ED, Brown MC, Schaffer R, et al (1995) Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant 16:213-222
3. Antman K, Eder JP, Elias A, et al (1987) High-dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 71:119-125
4. Barbounis V, Koumakis G, Vassilomanolakis M, et al (1995) A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Support Care Cancer 3:301-306
5. Beck TM (1995) The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs 6:237-242
6. Bosi A, Guidi S, Messori A, et al (1993) Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study J Chemother 5:191-196
7. 3 antagonists to control acute emesis in blood stem cells transplantation (abstract). Support Care Cancer 4:253 (abstr 116)
8. Croockewit S (1990)The efficacy of ondansetron in emesis induced by total body irradiation. Proceedings of a Glaxo sponsored symposium at the European Society of Medical Oncology Meeting in Copenhagen, 2 December pp 15-17
9. Fox SM, Einhorn LH, Cox E, et al (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391-2395
10. Frakes LA, Brehm TL, Kosty MP, et al (1997) An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20:473-478
11. Glaxo Wellcome (1996) Product information for Zofran® injection. Glaxo Wellcome
12. Grunberg SM, Hesketh PJ (1993)Control of chemotherapy-induced emesis. N Engl J Med 329:1790-1796
13. Hesketh PJ, Harvey WH, Harker WG, et al (1994) A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 12:596-600
14. Hesketh PJ, Kris MG, Grunberg et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15:103-109
15. Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
16. Jones AL, Hill AS, Soukop M, et al (1991) Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483-487
17. Kris MG, Gralla RJ, Tyson LB, et al (1989) Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7:108-114
18. Lacerda JF, Carmo JA, Pereira ME, et al (1996) A randomized trial of ondansetron (OND), granisetron (GRA) and tropisetron (TRO) in the prophylaxis of acute nausea and vomiting in bone marrow transplantation (BMT). Blood 88 [S1]:a1649:415a
19. Lazarus HM, Bryson JC, Lemon E, et al (1990) Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation. J Natl Cancer Inst 82:1776-1778
20. Lazarus HM, Creger RJ, Blumer JL, et al (1996) Randomized double-blind evaluation of bolus-dose vs continuous infusion granisetron to prevent vomiting in patients undergoing autotransplant. ISEH
21. Malik IA, Khan WA, Qazilbash M, et al (1995) Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. Am J Clin Oncol 18:170-175
22. Marty M (1989) Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Eur J Cancer Clin Oncol 25 [Suppl 1]:S41-45
23. Marty M, d'Allens H (1990) A single daily dose (SD) of ondansetron (OND) is as effective as a continuous infusion (CI) in the prevention of cisplatin (DDP)-induced nausea (N) and vomiting (V). Ann Oncol 1[Suppl]:112 (abstract WP:14)
24. Peters WP, Eder JP, Henner WD, et al (1986) High-dose combination alkylating agents with autologous bone marrow support: A phase I trial. J Clin Oncol 4:646-654
25. Viner CV, Selby PJ, Zulian GB, et al (1990) Ondansetron - a new safe and effective antiemetic in patients receiving high-dose melphalan. Cancer Chemother Pharmacol 25:449-453